For HR-MDS, IRAK4-L promotes leukemogenesis through NF-κB signaling [17,38] and a small molecule CA-4948 of oral IRAK4 inhibitor is currently evaluated in a phase 1 trial for HR-MDS and AML (NCT04278768) [106]. This evidence concerns the gene IRAK4 and myelodysplastic syndrome.